Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

Rulaxx1574 Feb. 19 at 11:34 PM

$VYNE thrilling!!

1 · Reply

Rulaxx1574 Feb. 19 at 4:05 PM

$VYNE moved a penny up, so the phony pumpers are back.

0 · Reply

No_Face_character Feb. 19 at 1:47 AM

$VYNE 👍

0 · Reply

Stock__Hunter Feb. 18 at 6:57 PM

$VYNE someone loaded boat 1/2 days.. be at train station early

0 · Reply

hiTHit Feb. 18 at 6:03 PM

$VYNE If we didn't have feet, we wouldn't wear shoes, and if we didn't have hands, we wouldn't wear gloves. So why do we carry a wallet?

0 · Reply

Stock__Hunter Feb. 18 at 4:09 PM

$VYNE she likes to sleep in sometimes, vol.. on watch, theres something brewing behind curtain

0 · Reply

Gtrading1234 Feb. 18 at 1:34 AM

$VYNE

0 · Reply

Digitalization2026 Feb. 17 at 7:32 PM

$CETX 👀 👀 ALRIGHT. DUMP IT BOYZ $OLB $VYNE $INTS $IVF

0 · Reply

Duskfall Feb. 17 at 7:20 PM

$OLB 🔥🔥🔥LFG🔥🔥🔥 $VYNE $INTS $IVF

0 · Reply

Duskfall Feb. 17 at 5:03 PM

$OLB Target $3+ $VYNE $INTS $IVF

0 · Reply

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Dec 17, 2025, 8:00 AM EST - 2 months ago

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

Nov 6, 2025, 8:00 AM EST - 3 months ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 7 months ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 8 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 10 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 10 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 10 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 1 year ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 1 year ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 3 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 3 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Rulaxx1574 Feb. 19 at 11:34 PM

$VYNE thrilling!!

1 · Reply

Rulaxx1574 Feb. 19 at 4:05 PM

$VYNE moved a penny up, so the phony pumpers are back.

0 · Reply

No_Face_character Feb. 19 at 1:47 AM

$VYNE 👍

0 · Reply

Stock__Hunter Feb. 18 at 6:57 PM

$VYNE someone loaded boat 1/2 days.. be at train station early

0 · Reply

hiTHit Feb. 18 at 6:03 PM

$VYNE If we didn't have feet, we wouldn't wear shoes, and if we didn't have hands, we wouldn't wear gloves. So why do we carry a wallet?

0 · Reply

Stock__Hunter Feb. 18 at 4:09 PM

$VYNE she likes to sleep in sometimes, vol.. on watch, theres something brewing behind curtain

0 · Reply

Gtrading1234 Feb. 18 at 1:34 AM

$VYNE

0 · Reply

Digitalization2026 Feb. 17 at 7:32 PM

$CETX 👀 👀 ALRIGHT. DUMP IT BOYZ $OLB $VYNE $INTS $IVF

0 · Reply

Duskfall Feb. 17 at 7:20 PM

$OLB 🔥🔥🔥LFG🔥🔥🔥 $VYNE $INTS $IVF

0 · Reply

Duskfall Feb. 17 at 5:03 PM

$OLB Target $3+ $VYNE $INTS $IVF

0 · Reply

hiTHit Feb. 17 at 4:38 PM

$VYNE After jumping from the plane to the ground, you need to open your parachute at an altitude of 760 meters above the ground. There is no sign in the air showing 760 meters. You must visually estimate the distance as 760 meters. Of course, if you have an eye that can guess.

0 · Reply

Duskfall Feb. 17 at 3:44 PM

There 👍 $OLB $VYNE

1 · Reply

PortfolioEclipse Feb. 17 at 1:27 PM

$VYNE Pre-revenue biotech; early-stage.

2 · Reply

Rulaxx1574 Feb. 11 at 4:06 PM

$VYNE wonder if the CEO even bothers to go to the office anymore?

1 · Reply

LuminaTrades Feb. 9 at 3:40 PM

$VYNE Dermatology biotech; faces competition in the aesthetics market.

1 · Reply

hiTHit Feb. 9 at 3:39 PM

$VYNE Since there's no one else here but me, I can't laugh alone.

2 · Reply

hiTHit Feb. 5 at 5:51 PM

$VYNE When I drive, the car consumes more fuel in the city than outside the city. How does my car know it's in the city? Probably with the help of navigation.🤓

2 · Reply

hiTHit Feb. 3 at 4:03 PM

$VYNE A thief broke into my house and stole everything except my Vyne stock. This idiot thief probably doesn't want to get rich.🤓

0 · Reply

Stock__Hunter Feb. 3 at 3:04 PM

$VYNE 👀

2 · Reply

OfficialStocktwitsUser Feb. 3 at 2:26 PM

$VYNE RSI: 62.22, MACD: 0.0166 Vol: 0.01, MA20: 0.57, MA50: 0.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

hiTHit Feb. 2 at 3:44 PM

$VYNE There are too many people in our elevator and it can't go up. Please, first remove 10,000 people from the elevator immediately. You're not doing any good here anyway.

2 · Reply

hiTHit Jan. 29 at 5:01 PM

$VYNE I informed the CEO that I would sell my gold and invest in shares. He said to me, “Don't bother buying shares. I'll transfer the entire company to you in exchange for your gold.”🤓

0 · Reply

Market Cap	19.80M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	275,300
Avg Vol	6,296,718
Day's Range	N/A - N/A
Shares Out	33.29M
Stochastic %K	84%
Beta	2.02
Analysts	Sell
Price Target	$2.00